Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05380492 · ClinicalTrials.gov registry record · Phase 1

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

A Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, sponsored by Perceive Biotherapeutics.

Compiled by PlainTrial · August 8, 2026

Active
Registry status: Phase 1
Development phase: 45
Enrollment target: 3
Study locations

NCT05380492: Active Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, sponsored by Perceive Biotherapeutics.

NCT05380492 is a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy that is active but no longer recruiting, run by Perceive Biotherapeutics. The registered enrollment target is 45 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05380492, a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, is active but no longer recruiting, sponsored by Perceive Biotherapeutics.

ACTIVE NOT RECRUITING
Registry status: Phase 1
Development phase: 45 participants
Enrollment target: 3
Study locations

Study Summary

This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.

Conditions Studied

Interventions

BIOLOGICAL VOY-101

Study Locations (3)

Massachusetts

Ophthalmic Consultants of Boston - Boston

Texas

Retina Consultants of Texas - Bellaire

Utah

University of Utah - Salt Lake City

Trial Details

Field	Value
Enrollment Target	45 participants
Start Date	2022-11-17
Est. Completion	2025-11
Phase	Phase 1

Perceive Biotherapeutics

2 total trials

What the registry record for NCT05380492 still lists

NCT05380492 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which VOY-101 is the first listed.

NCT05380492 reports a single indexed study location in Massachusetts, Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT05380492 about?

NCT05380492 is a clinical study titled "Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration". This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.

What is the current status of trial NCT05380492?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2022-11-17. Estimated completion is 2025-11.

What conditions does trial NCT05380492 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration, Geographic Atrophy.

What interventions are being tested in trial NCT05380492?

The interventions under investigation include: VOY-101 (BIOLOGICAL).

Who is sponsoring clinical trial NCT05380492?

This trial is sponsored by Perceive Biotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05380492 being conducted?

This trial has 3 study locations across Massachusetts, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05380492's enrollment target sits among peer trials

45 51st of 74 higher than 24 of 74 other Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05380492, the US trial registry maintained by the National Library of Medicine. NCT05380492 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.